Title:
BISPECIFIC ANTIBODY BINDING EGFR AND B7-H3
Document Type and Number:
WIPO Patent Application WO/2023/246891
Kind Code:
A1
Abstract:
Provided is an artificially designed bispecific antibody molecule, in particular an anti-B7-H3/EGFR bispecific antibody molecule, which can bind B7-H3 and EGFR at the same time.
Inventors:
HE KAIJIE (CN)
ZHOU SHUAIXIANG (CN)
GUAN JIAN (CN)
LI YANING (CN)
LIU XIYANG (CN)
ZHOU SHUAIXIANG (CN)
GUAN JIAN (CN)
LI YANING (CN)
LIU XIYANG (CN)
Application Number:
PCT/CN2023/101807
Publication Date:
December 28, 2023
Filing Date:
June 21, 2023
Export Citation:
Assignee:
INNOVENT BIOLOGICS SINGAPORE PTE LTD (SG)
International Classes:
C07K16/46; A61K39/395; A61P35/00; C07K16/28; C12N15/13
Domestic Patent References:
| WO2021081052A1 | 2021-04-29 | |||
| WO2022104236A2 | 2022-05-19 | |||
| WO2022135467A1 | 2022-06-30 |
Foreign References:
| CN111944050A | 2020-11-17 |
Other References:
SONG JIANXIANG, SHI WODA, ZHANG YAJUN, SUN MINGZHONG, LIANG XIAODONG, ZHENG SHIYING: "Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis", ONCOTARGETS AND THERAPY, vol. Volume 9, 1 October 2016 (2016-10-01), pages 6257 - 6263, XP093119910, ISSN: 1178-6930, DOI: 10.2147/OTT.S111691
HUANG, C. ET AL.: "Combination Therapy with B7H3-redirected Bispecific Antibody and Sorafenib Elicits Enhanced Synergistic Antitumor Efficacy", THERANOSTICS, vol. 10, no. 23, 31 December 2020 (2020-12-31), pages 10498 - 10512, XP093039750, DOI: 10.7150/thno.49480
MEWS ELLIE, JACKSON PAULINE, KILIC OZGUN, DELGADO JUSTINE, PATCHAVA MAHATHI, LARGAESPADA DAVID, WAGNER CARSTON R.: "Abstract 1823: Directing T cells using multivalent, bispecific chemically self-assembling nanorings (CSANs) to target brain tumors overexpressing EGFR and B7H3 antigens", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 13_Supplement, 1 July 2021 (2021-07-01), US, pages 1823 - 1823, XP093119912, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-1823
HUANG, C. ET AL.: "Combination Therapy with B7H3-redirected Bispecific Antibody and Sorafenib Elicits Enhanced Synergistic Antitumor Efficacy", THERANOSTICS, vol. 10, no. 23, 31 December 2020 (2020-12-31), pages 10498 - 10512, XP093039750, DOI: 10.7150/thno.49480
MEWS ELLIE, JACKSON PAULINE, KILIC OZGUN, DELGADO JUSTINE, PATCHAVA MAHATHI, LARGAESPADA DAVID, WAGNER CARSTON R.: "Abstract 1823: Directing T cells using multivalent, bispecific chemically self-assembling nanorings (CSANs) to target brain tumors overexpressing EGFR and B7H3 antigens", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 13_Supplement, 1 July 2021 (2021-07-01), US, pages 1823 - 1823, XP093119912, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-1823
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF:
Previous Patent: HANDOVER PROCESSING METHOD AND APPARATUS, AND COMMUNICATION DEVICE
Next Patent: SHAPED CATALYST BODY
Next Patent: SHAPED CATALYST BODY